secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jaguar Health, Inc. (JAGX)
CIK:        0001585608
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0001104659-23-115795
Event type: regulatory
Sentiment:  neutral
Materiality: 0.60
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants Jaguar Health additional 180-day grace period to regain $1.00 bid price compliance
--------------------------------------------------------------------------------

- Nasdaq extended compliance deadline to May 6, 2024; company must close at $1.00+ for 10 consecutive business days.
- Second 180-day period follows initial non-compliance notice filed May 12, 2023.
- CEO Lisa Conte notes Phase 3 OnTarget trial of Mytesi for chemotherapy-induced overactive bowel; top-line results expected before Thanksgiving 2023.
- Investigator-initiated studies for MVID and SBS ongoing, results expected by end of 2023 and into 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923115795/0001104659-23-115795-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1585608/000110465923115795/tm2330239d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-115795

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer